Compare RGP & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | AARD |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.5M | 165.8M |
| IPO Year | 2000 | 2025 |
| Metric | RGP | AARD |
|---|---|---|
| Price | $4.46 | $5.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $7.00 | ★ $15.29 |
| AVG Volume (30 Days) | ★ 267.4K | 116.2K |
| Earning Date | 04-08-2026 | 05-14-2026 |
| Dividend Yield | ★ 6.85% | N/A |
| EPS Growth | ★ 79.14 | 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $452,006,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.06 | $3.35 |
| 52 Week High | $5.55 | $17.94 |
| Indicator | RGP | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 58.02 | 45.48 |
| Support Level | $4.17 | $5.12 |
| Resistance Level | $4.54 | $6.43 |
| Average True Range (ATR) | 0.13 | 0.82 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 89.02 | 29.41 |
Resources Connection Inc is a professional services firm. Its segments include On-Demand Talent provides businesses with a go-to source for bringing in experts when its needed, serving the office of the CFO; Consulting drives transformation across people, processes and technology across domain areas including finance, technology and digital, risk and compliance and operational performance; Europe & Asia Pacific offers both on-demand and consulting services to clients throughout Europe and Asia Pacific; Outsourced Services; and Sitrick. It derives the majority of revenue from On-Demand Talent segment. Geographically, it operates in United States and internationally.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.